Sanofi
SAN
Rank in Stocks
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Share Price
$83.84
Market Cap
$100.45B
Change (1 day)
1.48%
Change (1 year)
-16.74%
Country
FR
Trade Sanofi (SAN)
Category
Healthcare
P/E ratio for Sanofi (SAN)
P/E ratio as of October 2026 TTM: 22.92
According to Sanofi latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.92. At the end of 2024 the company had a P/E ratio of 21.10.
P/E ratio history for Sanofi from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 22.92 | 77.27% |
| 2025 | 12.93 | -38.74% |
| 2024 | 21.10 | 1.40% |
| 2023 | 20.81 | 54.85% |
| 2022 | 13.44 | -24.64% |
| 2021 | 17.83 | 122.16% |
| 2020 | 8.02 | -80.27% |
| 2019 | 40.67 | 85.62% |
| 2018 | 21.91 | 104.46% |
| 2017 | 10.72 | -48.99% |
| 2016 | 21.01 | -12.27% |
| 2015 | 23.95 | 5.61% |
| 2014 | 22.68 | -17.41% |
| 2013 | 27.46 | 42.49% |
| 2012 | 19.27 | 46.27% |
| 2011 | 13.18 | -8.09% |
| 2010 | 14.34 | 4.92% |
| 2009 | 13.66 | 65.17% |
| 2008 | 8.27 | -48.59% |
| 2007 | 16.09 | -32.21% |
| 2006 | 23.74 | -45.86% |
| 2005 | 43.84 | -317.87% |
| 2004 | -20.12 | -199.40% |
| 2003 | 20.24 | -15.94% |
| 2002 | 24.08 | -37.41% |
| 2001 | 38.47 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 43.73 | 90.79% |
US
|
|
| 39.77 | 73.51% |
US
|
|
| 80.21 | 249.97% |
US
|
|
| 121.17 | 428.64% |
US
|
|
| 25.53 | 11.37% |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.